{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T23:08:45Z","timestamp":1794956925657,"version":"4.9.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Brian Eaton Memorial"},{"DOI":"10.13039\/501100006630","name":"Lung Foundation Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006630","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Thoracic Society of Australia & New Zealand","id":[{"id":"https:\/\/ror.org\/04mz79w33","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","award":["GNT1162767"],"award-info":[{"award-number":["GNT1162767"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Australian Scleroderma Interest Group"},{"name":"Australian Scleroderma Cohort Study"},{"name":"Australian Rheumatology Association","id":[{"id":"https:\/\/ror.org\/02z0zbb37","id-type":"ROR","asserted-by":"crossref"}]},{"name":"St Vincent\u2019s Hospital Melbourne Information Technology Department","id":[{"id":"https:\/\/ror.org\/001kjn539","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Scleroderma Clinical Trials Consortium, Boehringer-Ingelheim and Bayer"},{"DOI":"10.13039\/501100006630","name":"Lung Foundation Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006630","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Department of Allergy and Clinical Immunology and Department of Respiratory"},{"name":"Royal Prince Alfred Hospital","id":[{"id":"https:\/\/ror.org\/05gpvde20","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001774","name":"University of Sydney","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001774","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Centre of Research Excellence in Pulmonary Fibrosis"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate the prognostic utility of 28 serum biomarkers in systemic sclerosis (SSc), SSc-associated interstitial lung disease (SSc-ILD) and clinically relevant disease subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants with sera, high-resolution CT and lung function within 12\u2009months of baseline were identified from the Australian Scleroderma Cohort Study. Baseline was the time of serum collection. Twenty-seven of the prespecified 28 serum biomarkers were analysed and biomarker associations with mortality and ILD progression were investigated in univariable and multivariable analyses, including within disease subgroups and combined with established risk factors for poorer prognosis in SSc.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 407 participants were identified, 252 (61.9%) with SSc-ILD. The median (interquartile range) follow-up after biomarker measurement was 6.31 (3.11\u20139.22) years. Sixteen biomarkers were associated with increased mortality. High levels of VCAM-1 were most strongly associated with mortality [hazard ratio (HR) 3.55; 95% CI 2.37\u20135.33; P\u2009&amp;lt;\u20090.001]. Five additional biomarkers had an HR &amp;gt;2: SP-D (2.28, 1.57\u20133.31; P\u2009&amp;lt;\u20090.001), E-selectin (2.19, 1.53\u20133.14; P\u2009&amp;lt;\u20090.001), IL-6 (2.15, 1.50\u20133.09; P\u2009&amp;lt;\u20090.001), MMP-3 (2.05, 1.42\u20132.95; P\u2009&amp;lt;\u20090.001) and ET-1 (2.03, 1.40\u20132.92; P\u2009&amp;lt;\u20090.001). Eleven biomarkers were independently associated with mortality following adjustment for sex, age and baseline forced vital capacity (FVC%predicted). Three biomarkers were associated with ILD progression at 1-year follow-up: CXCL4 (odds ratio 2.67, 1.46\u20134.88; P\u2009=\u20090.001), MMP-1 (2.56, 1.43\u20134.59; P\u2009=\u20090.002) and ET-1 (2.18, 1.24\u20133.83; P\u2009=\u20090.007).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Multiple biomarkers, especially VCAM-1, E-selectin, SP-D and CXCL4, provide prognostic utility beyond that of established risk factors for patients with SSc.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae110","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:23:18Z","timestamp":1707783798000},"page":"2981-2988","source":"Crossref","is-referenced-by-count":20,"title":["Multiple serum biomarkers associate with mortality and interstitial lung disease progression in systemic sclerosis"],"prefix":"10.1093","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6550-1995","authenticated-orcid":false,"given":"Matthew James Sinclair","family":"Parker","sequence":"first","affiliation":[{"name":"Faculty of Medicine and Health, The University of Sydney , Sydney,","place":["Australia"]},{"name":"Rheumatology Department, RPA Institute for Academic Medicine, Royal Prince Alfred Hospital , Sydney,","place":["Australia"]},{"name":"NHMRC Centre of Research Excellence in Pulmonary Fibrosis , Sydney,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adelle S","family":"Jee","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, The University of Sydney , Sydney,","place":["Australia"]},{"name":"NHMRC Centre of Research Excellence in Pulmonary Fibrosis , Sydney,","place":["Australia"]},{"name":"Department of Respiratory Medicine, Royal Prince Alfred Hospital , Sydney,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Hansen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, St Vincent\u2019s Hospital , Melbourne,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Proudman","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Royal Adelaide Hospital , Adelaide,","place":["Australia"]},{"name":"Discipline of Medicine, University of Adelaide , Adelaide,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Youssef","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, The University of Sydney , Sydney,","place":["Australia"]},{"name":"Rheumatology Department, RPA Institute for Academic Medicine, Royal Prince Alfred Hospital , Sydney,","place":["Australia"]},{"name":"Institute for Musculoskeletal Health , Camperdown, Sydney,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony J","family":"Kenna","sequence":"additional","affiliation":[{"name":"Centre for Immunology and Infection Control, School of Biomedical Sciences, Queensland University of Technology , Brisbane,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Stevens","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, St Vincent\u2019s Hospital , Melbourne,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandana","family":"Nikpour","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, St Vincent\u2019s Hospital , Melbourne,","place":["Australia"]},{"name":"Department of Medicine, The University of Melbourne , Melbourne,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Sahhar","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Monash Health , Melbourne,","place":["Australia"]},{"name":"Department of Medicine, Central Clinical School, Monash University , Melbourne,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamera J","family":"Corte","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Health, The University of Sydney , Sydney,","place":["Australia"]},{"name":"NHMRC Centre of Research Excellence in Pulmonary Fibrosis , Sydney,","place":["Australia"]},{"name":"Department of Respiratory Medicine, Royal Prince Alfred Hospital , Sydney,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,2,15]]},"reference":[{"key":"2024110419231428700_keae110-B1","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","article-title":"Scleroderma","volume":"360","author":"Gabrielli","year":"2009","journal-title":"N Engl J Med"},{"key":"2024110419231428700_keae110-B2","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/rheumatology\/ker269","article-title":"Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies","volume":"51","author":"Elhai","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2024110419231428700_keae110-B3","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in causes of death in systemic sclerosis, 1972-2002","volume":"66","author":"Steen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"2024110419231428700_keae110-B4","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and predicting mortality from systemic sclerosis","volume":"76","author":"Elhai","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2024110419231428700_keae110-B5","doi-asserted-by":"crossref","first-page":"200340","DOI":"10.1183\/16000617.0340-2020","article-title":"Natural variability in the disease course of SSc-ILD: implications for treatment","volume":"30","author":"Vonk","year":"2021","journal-title":"Eur Respir Rev"},{"key":"2024110419231428700_keae110-B6","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1164\/rccm.201903-0563CI","article-title":"Etiology, risk factors, and biomarkers in systemic sclerosis with interstitial lung disease","volume":"201","author":"Khanna","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2024110419231428700_keae110-B7","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41584-018-0021-9","article-title":"Existing and novel biomarkers for precision medicine in systemic sclerosis","volume":"14","author":"Wermuth","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2024110419231428700_keae110-B8","doi-asserted-by":"crossref","first-page":"1902026","DOI":"10.1183\/13993003.02026-2019","article-title":"Predictors of progression in systemic sclerosis patients with interstitial lung disease","volume":"55","author":"Distler","year":"2020","journal-title":"Eur Respir J"},{"key":"2024110419231428700_keae110-B9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.pharmthera.2019.05.014","article-title":"Review: serum biomarkers in idiopathic pulmonary fibrosis and systemic sclerosis associated interstitial lung disease\u2014frontiers and horizons","volume":"202","author":"Jee","year":"2019","journal-title":"Pharmacol Ther"},{"key":"2024110419231428700_keae110-B10","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/art.42491","article-title":"A Composite Serum Biomarker Index for the Diagnosis of Systemic Sclerosis-Associated Interstitial Lung Disease: a Multicenter, Observational Cohort Study","volume":"75","author":"Jee","year":"2023","journal-title":"Arthritis Rheumatol"},{"key":"2024110419231428700_keae110-B11","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"65","author":"van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"2024110419231428700_keae110-B12","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: a simple staging system","volume":"177","author":"Goh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"2024110419231428700_keae110-B13","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1183\/09031936.00080312","article-title":"Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations","volume":"40","author":"Quanjer","year":"2012","journal-title":"Eur Respir J"},{"key":"2024110419231428700_keae110-B14","doi-asserted-by":"crossref","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic definitions and updated clinical classification of pulmonary hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur Respir J"},{"key":"2024110419231428700_keae110-B15","volume-title":"Primary pulmonary hypertension: report on a WHO meeting","author":"Hatano","year":"1975"},{"key":"2024110419231428700_keae110-B16","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.3390\/ijms19041057","article-title":"Emerging Roles of Vascular Cell Adhesion Molecule-1 (VCAM-1) in immunological disorders and cancer","volume":"19","author":"Kong","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2024110419231428700_keae110-B17","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1093\/rheumatology\/34.11.1048","article-title":"Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis","volume":"34","author":"Denton","year":"1995","journal-title":"Br J Rheumatol"},{"key":"2024110419231428700_keae110-B18","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1164\/rccm.201101-0058OC","article-title":"Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis","volume":"185","author":"Richards","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"2024110419231428700_keae110-B19","doi-asserted-by":"crossref","first-page":"e88150","DOI":"10.1371\/journal.pone.0088150","article-title":"Serum adhesion molecule levels as prognostic markers in patients with early systemic sclerosis: a multicentre, prospective, observational study","volume":"9","author":"Hasegawa","year":"2014","journal-title":"PLoS One"},{"key":"2024110419231428700_keae110-B20","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/art.1780380206","article-title":"Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity","volume":"38","author":"Gruschwitz","year":"1995","journal-title":"Arthritis Rheum"},{"key":"2024110419231428700_keae110-B21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s10067-004-0987-3","article-title":"Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement","volume":"24","author":"Kuryliszyn-Moskal","year":"2005","journal-title":"Clin Rheumatol"},{"key":"2024110419231428700_keae110-B22","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00408-017-9993-5","article-title":"Blood Biomarkers in Idiopathic Pulmonary Fibrosis","volume":"195","author":"Guiot","year":"2017","journal-title":"Lung"},{"key":"2024110419231428700_keae110-B23","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0925-4439(98)00079-9","article-title":"Surfactant proteins A and D: disease markers","volume":"1408","author":"Kuroki","year":"1998","journal-title":"Biochim Biophys Acta"},{"key":"2024110419231428700_keae110-B24","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/1529-0131(200106)44:6<1363::AID-ART229>3.0.CO;2-5","article-title":"Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis","volume":"44","author":"Asano","year":"2001","journal-title":"Arthritis Rheum"},{"key":"2024110419231428700_keae110-B25","first-page":"1112","article-title":"Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis","volume":"31","author":"Yanaba","year":"2004","journal-title":"J Rheumatol"},{"key":"2024110419231428700_keae110-B26","doi-asserted-by":"crossref","first-page":"773","DOI":"10.3899\/jrheum.080633","article-title":"Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma","volume":"36","author":"Hant","year":"2009","journal-title":"J Rheumatol"},{"key":"2024110419231428700_keae110-B27","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.3899\/jrheum.120997","article-title":"Can serum surfactant protein D or CC-chemokine ligand 18 predict outcome of interstitial lung disease in patients with early systemic sclerosis?","volume":"40","author":"Elhaj","year":"2013","journal-title":"J Rheumatol"},{"key":"2024110419231428700_keae110-B28","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1002\/art.40815","article-title":"Performance of candidate serum biomarkers for systemic sclerosis-associated interstitial lung disease","volume":"71","author":"Elhai","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2024110419231428700_keae110-B29","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.autrev.2011.04.019","article-title":"Angiogenic cytokines and growth factors in systemic sclerosis","volume":"10","author":"Liakouli","year":"2011","journal-title":"Autoimmun Rev"},{"key":"2024110419231428700_keae110-B30","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1755-1536-4-15","article-title":"Altered monocyte and fibrocyte phenotype and function in scleroderma interstitial lung disease: reversal by caveolin-1 scaffolding domain peptide","volume":"4","author":"Tourkina","year":"2011","journal-title":"Fibrogenesis Tissue Repair"},{"key":"2024110419231428700_keae110-B31","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/1756-185X.14037","article-title":"Association of serum CXCL12 levels with arthropathy in patients with systemic sclerosis","volume":"24","author":"Ikawa","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"2024110419231428700_keae110-B32","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1136\/ard.2008.098277","article-title":"Association between a stromal cell-derived factor 1 (SDF-1\/CXCL12) gene polymorphism and microvascular disease in systemic sclerosis","volume":"68","author":"Manetti","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2024110419231428700_keae110-B33","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.3390\/jcm9113388","article-title":"Potential biomarkers in systemic sclerosis: a literature review and update","volume":"9","author":"Utsunomiya","year":"2020","journal-title":"J Clin Med"},{"key":"2024110419231428700_keae110-B34","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa1114576","article-title":"Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis","volume":"370","author":"van Bon","year":"2014","journal-title":"N Engl J Med"},{"key":"2024110419231428700_keae110-B35","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1038\/s41467-019-09683-z","article-title":"CXCL4 assembles DNA into liquid crystalline complexes to amplify TLR9-mediated interferon-alpha production in systemic sclerosis","volume":"10","author":"Lande","year":"2019","journal-title":"Nat Commun"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae110\/56793535\/keae110.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/11\/2981\/60415631\/keae110.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/63\/11\/2981\/60415631\/keae110.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T14:23:41Z","timestamp":1730730221000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/63\/11\/2981\/7609049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,15]]},"references-count":35,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,2,15]]},"published-print":{"date-parts":[[2024,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae110","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,2,15]]}}}